Sarcoma / 2019 / Article / Tab 2

Clinical Study

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Table 2

Tumor response evaluation based on the WHO and RECIST criteria (stage 1: 15 patients; stage 2: 10 patients).

Response evaluationStage 1Stage 2
Cycle 2 (N = 15)Cycle 4 (N = 8)Cycle 2 (N = 10)Cycle 4 (N = 5)

WHO
 Partial response1000
 Stable disease7152
 Progressive disease5543
 Others2210
RECIST
 Partial response0000
 Stable disease9254
 Progressive disease4441
 Others2210

Partial response was unconfirmed and thus not counted as clinical benefit.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.